We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

85 hedge funds and large institutions have $109M invested in Calithera Biosciences, Inc in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 21

8% less funds holding

Funds holding: 9285 (-7)

18% less capital invested

Capital invested by funds: $134M → $109M (-$24.5M)

35% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 20

42% less call options, than puts

Call options by funds: $127K | Put options by funds: $218K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
85
Holders Change
-7
Holders Change %
-7.61%
% of All Funds
1.86%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
13
Increased
38
Reduced
21
Closed
20
Calls
$127K
Puts
$218K
Net Calls
-$91K
Net Calls Change
-$373K
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$21.4M +$5.8M +72,463 +26%
BI
2
BVF Inc
California
$20.9M
BlackRock
3
BlackRock
New York
$12.7M +$3.57M +44,589 +28%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$10.4M -$672K -8,400 -5%
Vanguard Group
5
Vanguard Group
Pennsylvania
$7.2M +$870K +10,874 +10%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$4.58M +$73.8K +922 +1%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$4.02M +$400K +5,000 +8%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$3.71M -$2.95M -36,790 -38%
Renaissance Technologies
9
Renaissance Technologies
New York
$3.33M +$1.32M +16,430 +44%
SI
10
Sofinnova Investments
California
$2.98M +$1.74M +21,751 +82%
State Street
11
State Street
Massachusetts
$2.28M +$271K +3,381 +10%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.76M +$387K +4,829 +20%
N
13
Nuveen
North Carolina
$1.76M +$489K +6,108 +27%
Northern Trust
14
Northern Trust
Illinois
$1.65M +$550K +6,873 +35%
OAM
15
Oxford Asset Management
United Kingdom
$731K +$363K +4,539 +62%
JP Morgan Chase
16
JP Morgan Chase
New York
$703K +$873K +10,901 +2,305%
BCM
17
Bridgeway Capital Management
Texas
$624K +$200K +2,500 +33%
Man Group
18
Man Group
United Kingdom
$600K -$694K -8,671 -47%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$516K +$123K +1,537 +23%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$496K +$397K +4,960 +162%
Wells Fargo
21
Wells Fargo
California
$489K +$253K +3,161 +67%
Millennium Management
22
Millennium Management
New York
$392K +$509K +6,359 New
Goldman Sachs
23
Goldman Sachs
New York
$360K -$247K -3,089 -35%
FSA
24
Franklin Street Advisors
North Carolina
$348K
Charles Schwab
25
Charles Schwab
California
$336K +$98.5K +1,231 +29%

CALA Hedge Fund Activity: Q3 2019 in Review

85 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q3 2019, worth a combined $109M — down 18% from $134M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CALA and 13 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 38 added.

The largest buyer was Federated Hermes, adding an estimated $5.8M. The largest seller was CVI Holdings, exiting entirely with an estimated $3.29M sold.

  • 85 institutional investors held Calithera Biosciences, Inc (CALA) as of Q3 2019, down from 92 in Q2 2019.
  • Funds reported $109M of Calithera Biosciences, Inc stock for Q3 2019, down 18% quarter-over-quarter.
  • 13 funds opened new Calithera Biosciences, Inc positions in Q3 2019 and 20 closed out, a net change of -7 holders.
  • The largest Calithera Biosciences, Inc buyer in Q3 2019 was Federated Hermes, an estimated $5.8M added.
  • The largest Calithera Biosciences, Inc seller in Q3 2019 was CVI Holdings, an estimated $3.29M sold.

Based on aggregated 13F filings for Q3 2019.